What the anaesthetists said, and then said again
A drug that delays gastric emptying complicates the assumption behind every fasting instruction in perioperative medicine. The professional bodies have moved twice on this…
Dosing
Page 8 of 31 of this archive, newest first.
GIP was a failed target for thirty years. Then it was not.
A dual agonist is one molecule with two receptor activities. A co-formulation is two molecules in one pen. The coverage treats them as synonyms.
The Netherlands pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new Norway guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A supply gap is a pharmacological event
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
The effect profile, predicted from an expression map
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
The mechanism behind the mechanism
The clinical effect profile is almost fully predictable from where the receptor is expressed, which is unusual and useful.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
India pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
A calculation you should do twice and write down once
Every time a vial changes, the conversion must be recalculated. Carrying forward a unit count from the last vial is the single most reliable way to give the wrong dose.
Reading the semaglutide titration schedule as a regulatory artefact
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Mapping a rotation that you will actually follow
The evidence base here is the insulin injection-technique literature, which is large and transfers well on tissue questions.
What a month without the drug does to tolerability
The convention — resume lower, re-escalate — is not caution. It follows directly from the elimination half-life.
Poland pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Sweden pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
The eighteenth month, and the conversation that should have happened in the third
Two withdrawal-design trials tell us what happens when treatment stops. Neither tells us what the lowest effective maintenance dose is.